 HGH, produced by the pituitary gland, controls muscle and bone growth and lowers the amount of fat in the body
The major role of HGH is to stimulate the liver and other tissues to secrete IGF-I. IGF-I stimulates the proliferation of chondrocytes (cartilage cells), resulting in bone growth. IGF-I also appears to be the key player in muscle growth. It stimulates both the differentiation and proliferation of myoblasts. It also stimulates amino acid uptake and protein synthesis in muscle and other tissues.
In addition, HGH has important consequences for protein, lipid and carbohydrate metabolism. In some cases, a direct effect of growth hormone has been clearly demonstrated, in others, IGF-I is thought to be the critical mediator, and in some cases it appears that both direct and indirect effects are at play.
Growth hormone production is modulated by many factors, including stress, exercise, nutrition, sleep and growth hormone itself. However, its primary controllers are two hypothalamic hormones and one hormone from the stomach.
HGH levels dramatically decline with age. By the age of 60 most people will have approximately 80% less growth hormone in their system than when they were 20. Signs of GH reduction include increased body fat, increased anxiety, social isolation, poor general health, and lack of positive well being.
In 1988 Dr. Daniel Rudman discovered that when HGH was administered to his elderly patients, within several weeks they all noticed significant improvement. The benefits included a general feeling of enhanced well being, a reduction in feelings of depression, a decline in fat cells, an increase in lean muscle mass and, after a few months, increased skin thickness and elasticity.
Another important benefit from growth hormone replacement is strengthening of the immune system. Infections decrease, recovery from illness is aided, allergies improve and immune related diseases such as arthritis become less bothersome. The immune system is an important defense against cancer and it seems logical that cancer might, to some extent, be prevented by growth hormone. Although it has been speculated that growth hormone might speed the growth of cancer, that has not been seen in clinical practice. In fact, improved immunity might logically be expected to reduce the risk of malignancy and speed healing from a treated cancer.
Your physician's guidance and blood monitoring is essential on a program of Human Growth Hormone, and as usual amounts of this hormone are highest in our early twenties and decline rapidly as we age. Physicians administering HGH for preventative/ anti-aging purposes utilize in the region of 0.01mg to 0.02mg of HGH per Kg of body weight (that's 2.2 lbs.) per week. This is injected subcutaneously (just under the skin) divided into 3 to 5 injections per week.
Although the precise protocol has not been confirmed, most of the physicians we deal with adopt this type of program. However, it is important to ensure that blood levels of HGH are monitored before and during the program and that a full check-up by an Anti-Aging Physician is performed before the course of HGH injections begin.
Human growth hormone supplements decline in frequency and sometimes stop for a period once the patient has reached a IGF1 blood plasma test equivalent to that of a 21 to 31 year old, again physicians differ on the line, some advocate early twenties, others early thirties measures.
We are now providing the Serono Human Growth Hormone called Saizen. This product has some advantages in shipping. Firstly it is stable at room temperature (before the product is constituted), and it also lasts longer once constituted (when it has to then be kept in a fridge). Once constituted, the product should be discarded after 30 days.
The ampoule bottle with lyophilised powder contains:
Somatropin .........1.33 mg
equivalent to ....... 4 IU
Excipient ........... s.q.
The small ampoule of diluting agent contains: 0.9% sodium chloride solution ........1 ml
Properties: The main active ingredient of Saizen is Somatropin, a biosynthetic human growth hormone produced from mammal cells through genetic engineering. It contains 191 amino acids, in identical sequence to that of the natural hypophysiary hormone. Saizen brings about an increase in the average growth rate by means of Somamedins or growth factors similar to insulin.
Contraindications: Individual hypersensitivity to the active component in the product. Diabetes mellitus must be considered as a relative contraindication. In subjects suffering from diabetes mellitus, treatment should be carried out under strict medical and laboratory supervision. Saizen must not be used when there are progression data of a concomitant cerebral tumour.
Side effects: Pharmacokinetic and toxicological studies carried out with Saizen and pit-HGH have confirmed that the safety of the recombinant product is similar to that of the natural growth hormone, with no side effects produced by the drug itself. However, treatment with human proteins can cause reactions as a result of hypersensitivity (such as redness and itchiness in the area of the injection site), the formation of antibodies with or without the attenuating effect of growth, or both.
In a small number of patients, where short stature is due to a genetic defect (depletion of the gene complex for HGH), Somatropin treatment can stimulate the production of antibodies which attenuate growth in the majority of cases.
Drug interactions: Concomitant therapy with corticoids may inhibit the growth promoting effect of Somatropin.
Directions for use: Saizen can be administered intramuscularly or subcutaneously, preferably at bedtime. The contents of one ampoule bottle must be reconstituted with the diluting agent, by inserting the liquid into the ampoule bottle and gently shaking it until it is completely dissolved. Do not shake it vigorously, as this can cause a slight darkening of the solution.
Store in the refrigerator at 2ºC to 8ºC. Do not freeze.
Do not use if the seal has been broken.
Do not use after the expiry date.
Once the mixture has been made, the product can be stored in the refrigerator at 2ºC - 8ºC.
Dosage: Follow your doctor's instructions.
Presentation: Box with 1 ampoule bottle with lyophilised powder, 1.33 mg equivalent to 4 IU, and 1 small ampoule with 1 ml of diluting agent.
Safety: Treatment must be carried out under strict periodic medical supervision. Patients with a deficiency of the growth hormone secondary to an intracraneal lesion should be examined frequently in order to follow the progression or recurrence of the underlying pathological process. Administering Saizen subcutaneously in the same site over a prolonged period of time may cause lipoatrophy. This can be prevented if the injection site is changed each time.
Keep out of children's reach.
Do not use if you are pregnant or breast-feeding.
Sold by medical prescription only.
The above information is the translation of the manufacturer's insert. It is provided under the supplying company's terms and conditions and should not replace the advice of your personal physician.
Disclaimer: This product and its statements have not been evaluated by the FDA. This product is not intended to treat, cure or prevent any disease. The above information is provided under the supplying company's terms and conditions and should not replace the advice of your personal physician.
Restrictions: This product cannot be shipped to Australia, Canada, EU, or Norway.
This product may be controlled in your country.
CLICK HERE TO BUY
|
